Back to Journals » Journal of Blood Medicine » Volume 8

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan

Authors Yoshimura H, Hotta M, Nakanishi T, Fujita S, Nakaya A, Satake A, Ito T, Ishii K, Nomura S

Received 28 September 2016

Accepted for publication 6 December 2016

Published 24 January 2017 Volume 2017:8 Pages 5—12


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Martin H. Bluth

Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Atsushi Satake, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura

First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan

Background: Biosimilar granulocyte colony-stimulating factor (G-CSF) has recently been introduced into clinical practice. G-CSFs are used to mobilize CD34+ cells and accelerate engraftment after transplantation. However, in Asia, particularly in Japan, data for peripheral blood stem cell (PBSC) mobilization by this biosimilar G-CSF are currently lacking. Therefore, the clinical efficacy and safety of biosimilar G-CSF for hematopoietic stem cell transplantation needs to be evaluated in a Japanese context.
Materials and methods: The subjects included two groups of patients with malignant lymphoma and multiple myeloma. All patients received chemotherapy priming for the mobilization of PBSCs. All patients were treated with chemotherapy followed by the administration of either the biosimilar G-CSF, filgrastim XM02 (FBNK), or the originators, filgrastim, or lenograstim.
Results: There were no significant differences among FBNK, filgrastim, and lenograstim treatments in the numbers of CD34+ cells in harvested PBSCs, the scores for granulocyte/macrophage colony forming units, or for malignant lymphoma and multiple myeloma patients evaluated as separate or combined cohorts. In addition, there were no significant differences in safety, side effects, complications, or the time to engraftment after autologous hematopoietic stem cell transplantation.
Conclusion: Biosimilar FBNK shows the same efficacy and safety as originator G-CSFs for facilitating bone marrow recovery in Japanese malignant lymphoma and multiple myeloma patients undergoing stem cell transplantation. In addition, it is less expensive than the originators, reducing hospitalization costs.

Keywords: G-CSF, biosimilar, peripheral blood stem cell, hematological malignancy, autologous hematopoietic stem cell transplantation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

Niki M, Yokoi T, Kurata T, Nomura S

Lung Cancer: Targets and Therapy 2017, 8:91-99

Published Date: 3 August 2017

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis

Okuda Y, Omoto S, Taniura T, Shouzu A, Nomura S

International Journal of General Medicine 2016, 9:65-71

Published Date: 12 April 2016

Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation

Nomura S, Maeda Y, Ishii K, Katayama Y, Yagi H, Fujishima N, Ota S, Moriyama M, Ikezoe T, Miyazaki Y, Hayashi K, Fujita S, Satake A, Ito T, Kyo T, Tanimoto M

Journal of Blood Medicine 2016, 7:1-4

Published Date: 18 January 2016

Trialing a new clinical clerkship record in Japanese clinical training

Nomura S, Tanigawa N, Kinoshita Y, Tomoda K

Advances in Medical Education and Practice 2015, 6:563-565

Published Date: 22 September 2015

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

Omoto S, Taniura T, Nishizawa T, Tamaki T, Shouzu A,Nomura S

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015, 8:339-345

Published Date: 27 July 2015

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation

Ozasa R, Hotta M, Yoshimura H, Nakanishi T, Tamaki T, Fujita S, Nakamichi N, Miyaji M, Ishii K, Ito T, Nomura S

International Medical Case Reports Journal 2012, 5:39-43

Published Date: 6 July 2012

Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients

Nomura S, Taniura T, Shouzu A, Omoto S, Inami N, Fujita S, Tamaki T, Yokoi T, Shimizu T, Ito T

International Journal of General Medicine 2012, 5:535-540

Published Date: 18 June 2012

A case of thrombotic thrombocytopenic purpura induced by acute pancreatitis

Arimoto M, Komiyama Y, Okamae F, Ichibe A, Teranishi S, Tokunaga H, Nakaya K, Fujiwara M, Yamaoka M, Onishi S, Miyamoto R, Nakamichi N, Nomura S

International Journal of General Medicine 2012, 5:307-311

Published Date: 28 March 2012

Antiplatelet antibody may cause delayed transfusion-related acute lung injury

Torii Y, Shimizu T, Yokoi T, Sugimoto H, Katashiba Y, Ozasa R, Fujita S, Adachi Y, Maki M, Nomura S

International Journal of General Medicine 2011, 4:677-680

Published Date: 12 September 2011

Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus

Nomura S, Omoto S, Yokoi T, Fujita S, Ozasa R, Eguchi N, Shouzu A

International Journal of General Medicine 2011, 4:539-545

Published Date: 20 July 2011